H1512

Haloperidol

powder

• Synonym(s): 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone
• Empirical Formula (Hill Notation): C₂₁H₂₃ClFNO₂
• CAS Number: 52-86-8
• Molecular Weight: 375.86
• EC Number: 200-155-6
• MDL number: MFCD00051423
• PubChem Substance ID: 24277917
• NACRES: NA.77

Properties

• Quality Level: 200
• form: powder
• color: white
• solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL; 0.1 M HCl: 3 mg/mL; DMSO: soluble; H₂O: insoluble; ethanol: soluble
• originator: Johnson & Johnson
• SMILES string: OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
• InChI: 1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
• InChI key: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Gene Information: human ... ABCB1(5243) , ADRA1A(148) , ADRA2A(150) , ADRA2C(152) , CHRM1(1128) , DRD2(1813) , DRD3(1814) , DRD4(1815) , EBP(10682) , HRH1(3269) , HTR2A(3356) , HTR2C(3358) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , PRNP(5621) ; rat ... Adra1a(29412) , Adra2a(25083) , Chrm1(25229) , Chrm2(81645) , Drd1a(24316) , Drd2(24318) , Drd3(29238) , Drd4(25432) , Hrh1(24448) , Htr1a(24473) , Htr1b(25075) , Htr2a(29595) , Htr2c(25187) , Oprs1(29336) , Slc6a3(24898) , Slc6a4(25553)

Description

Application

Haloperidol has been used:

• in ethanol to serves as an inhibitor of Erg2p
• to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines
• in receptor internalization assay
• as an antipsychotic drug in Dulbecco′s Modified Eagle medium

Packaging

5, 10, 25 g in glass bottle

Biochem/physiol Actions

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. H1512.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Safety Information

• Pictograms: GHS06,GHS08
• Signal Word: Danger
• Hazard Statements: H301 - H315 - H317 - H319 - H335 - H361
• Precautionary Statements: P201 - P280 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• Target Organs: Respiratory system
• Storage Class Code: 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable